EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of β-Lapachone as a Potent USP22 Inhibitor That Suppresses Cancer Stemness and Enhances Chemosensitivity in Lung Adenocarcinoma

Yuanyuan Gao, Keqiang Zhang, Wendong Li, John Liu, David Kwon, Lilian Gu, Aimin Li, Hongwei Holly Yin iD, Claudia Kowolik, Mahima Raul, David A Horne, Dan J Raz

International Journal of Molecular Sciences · 19.06.2026 · 27 (12) · 5561

DOI: 10.3390/ijms27125561 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.06.2026. Verfasst von Yuanyuan Gao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA. Hauptthemen laut MEDLINE: Naphthoquinones, Neoplastic Stem Cells, Lung Neoplasms, Ubiquitin Thiolesterase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: City Of Hope National Medical Center, United States Department of Defense, Integrated Drug Development Venture of City of Hope.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ubiquitin-specific protease 22 (USP22) regulates epigenetic gene expression by deubiquitinating histone H2B (H2Bub1) and upregulating oncogenic proteins and pathways, while antagonizing p53-mediated tumor suppression. USP22 is frequently overexpressed in cancers and associated with therapy resistance and poor prognosis yet remains largely untargeted pharmacologically. Here, using a fluorescence-based USP22 deubiquitinase assay to screen the LOPAC®1280 library, we identified β-Lapachone, a natural ortho-naphthoquinone with strong anticancer activities, as a potent USP22 inhibitor. β-Lapachone potently inhibited USP22 enzymatic activity, with a half-maximal inhibitory concentration (IC50) of ~0.75 μM, and molecular docking revealed its occupation of the catalytic pocket adjacent to the USP22 active-site triad, supporting a potential binding mode. Functionally, β-Lapachone suppressed proliferation and induced apoptosis in A549 and H1299 RAS-mutant lung adenocarcinoma (LUAD) cells, while USP22 knockout conferred marked resistance, indicating partial USP22 dependence. In patient-derived LUAD models, β-Lapachone inhibited sphere formation and reduced CD133+ cancer stem cell populations. Notably, it synergized with cisplatin to enhance DNA damage and apoptosis. In vivo, β-Lapachone significantly suppressed tumor growth in a syngeneic KRAS-mutant/p53-Null mouse lung cancer model and further potentiated cisplatin-induced antitumor effects. Collectively, these findings identify β-Lapachone as a potent inhibitor of USP22 and validate USP22 inhibition as a key mechanism underlying its anticancer activity in LUAD cells, both in vitro and in vivo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaphthoquinonesNeoplastic Stem CellsLung NeoplasmsUbiquitin ThiolesteraseAdenocarcinoma of LungAntineoplastic AgentsHumansAnimalsMiceCell ProliferationApoptosisCell Line, TumorMolecular Docking SimulationDrug Resistance, NeoplasmCisplatinXenograft Model Antitumor Assays

Stichwörter der Autor:innen

cancer stem cellschemosensitivitydeubiquitinase inhibitorlung adenocarcinoma (LUAD)ubiquitin-specific protease 22 (USP22)β-Lapachone

Substanzen

Naphthoquinonesbeta-lapachoneUsp22 protein, humanUbiquitin ThiolesteraseAntineoplastic AgentsCisplatin

Autor:innen und Institutionen

  • Division of Thoracic Surgery, City of Hope National Medical Center, Duarte, CA 91010, USA.
  • School of Basic Medicine, Ningxia Medical University, Yinchuan 750004, China.
  • Cancer Biology and Molecular Medicine, City of Hope Beckman Research Institute, Duarte, CA 91010, USA.
  • Pathology Core of Shared Resources, City of Hope National Medical Center, Duarte, CA 91010, USA.

ORCID-Profile: Hongwei Holly Yin

Förderung

  • City Of Hope National Medical Center
  • United States Department of Defense
  • Integrated Drug Development Venture of City of Hope
  • Department of Defense Lung Cancer Research Program
  • National Cancer Institute of the National Institutes of Health

Zitieren

APA

Gao, Y., Zhang, K., Li, W., Liu, J., Kwon, D., Gu, L., Li, A., Yin, H. H., Kowolik, C., Raul, M., Horne, D. A., & Raz, D. J. (2026). Identification of β-Lapachone as a Potent USP22 Inhibitor That Suppresses Cancer Stemness and Enhances Chemosensitivity in Lung Adenocarcinoma. International Journal of Molecular Sciences, 27(12), 5561. https://doi.org/10.3390/ijms27125561

Vancouver

Gao Y, Zhang K, Li W, Liu J, Kwon D, Gu L, et al. Identification of β-Lapachone as a Potent USP22 Inhibitor That Suppresses Cancer Stemness and Enhances Chemosensitivity in Lung Adenocarcinoma. International Journal of Molecular Sciences. 2026;27(12):5561. doi:10.3390/ijms27125561

BibTeX
@article{Gao2026,
  author = {Gao, Yuanyuan and Zhang, Keqiang and Li, Wendong and Liu, John and Kwon, David and Gu, Lilian and Li, Aimin and Yin, Hongwei Holly and Kowolik, Claudia and Raul, Mahima and Horne, David A and Raz, Dan J},
  title = {Identification of β-Lapachone as a Potent USP22 Inhibitor That Suppresses Cancer Stemness and Enhances Chemosensitivity in Lung Adenocarcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {12},
  pages = {5561},
  doi = {10.3390/ijms27125561}
}
Kostenlos starten →